Loading...
PhD Tihomir Tomašić

PhD Tihomir Tomašić
no.: 28334 source: ARIS

researcher – active in research organisation
E-mail tihomir.tomasicat signffa.uni-lj.si
Foreign language skills
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
B200  Biomedical sciences  Cytology, oncology, cancerology 
B230  Biomedical sciences  Microbiology, bacteriology, virology, mycology 
Keywords
drug design; inhibitor; molecular modelling; DNA gyrase; Hsp90; antibacterial activity; anticancer activity
Points
1,282.29
A''
218.48
A'
714.38
A1/2
915.11
CI10
2,194
CImax
203
h10
25
A1
4.66
A3
0.95
Data for the last 5 years (citations for the last 10 years) on July 14, 2024; A3 for period 2018-2022 (update for tender in 2023: YES)
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Database Linked records Citations Pure citations Average pure citations
WoS 119  2,580  2,116  17.78 
Scopus 123  2,865  2,336  18.99 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 Jaka Dernovšek  Bologna doctoral studies  10/1/2020 - 9/30/2024  54784 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
  B. Sc.     SI University of Ljubljana, Faculty of Pharmacy 2006 
Doctor's degree  Ph. D.     SI University of Ljubljana, Faculty of Pharmacy 2011 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (120%, RD:50%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry  11/1/2006  Professor  Researcher  Full professor 
Research projects Legend
source: ARIS
no. Code Title Period Head No. of publications
1. J1-50038  New Hsp90 Inhibitor-based Therapies for Ewing Sarcoma   2024  PhD Tihomir Tomašić  390 
2. J1-50023  3DfluorCO - Three-dimensional fluorine-based carbonyl bioisosteres: asymmetric synthesis and validation   2023 - 2024  PhD Andrej Emanuel Cotman  1,075 
3. J1-50037  Development of CDK1-selective degraders for the treatment of T-cell malignancies   2023 - 2024  PhD Izidor Sosič  1,132 
4. J1-4400  Evaluation of transient protein states   2022 - 2024  PhD Simona Golič Grdadolnik  3,283 
5. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   2022 - 2024  PhD Lucija Peterlin Mašič  6,134 
6. J3-4496  Next-generation adjuvants for mucosal vaccines   2022 - 2024  PhD Žiga Jakopin  1,237 
7. BI-HR/23-24-032  Evaluation of harmine analogues as potential Hsp90 inhibitors against pediatric sarcomas   2023 - 2024  PhD Tihomir Tomašić  390 
8. BI-AT/23-24-008  Development of Hsp90 C-terminal domain inhibitors for the treatment of pediatric sarcomas   2023 - 2024  PhD Tihomir Tomašić  390 
9. J1-3031  Development of new inhibitors of bacterial topoisomerases to overcome antimicrobial resistance   2021 - 2024  PhD Nace Zidar  1,061 
10. J1-3030  MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance   2021 - 2024  PhD Lucija Peterlin Mašič  979 
11. J3-2517  Development of innate immune receptor-targeting chimeras as custom-tailored vaccine adjuvants   2020 - 2023  PhD Žiga Jakopin  2,252 
12. J1-2483  Radiopharmaceuticals with antagonistic activity on CCK2R   2020 - 2023  PhD Marko Anderluh  1,079 
13. J1-2485  The kiss of death for key apoptosis players: development of BCL-2 and BAX PROTACs   2020 - 2023  PhD Izidor Sosič  987 
14. J1-1717  Development of novel Hsp90 inhibitors with anticancer activity   2019 - 2023  PhD Tihomir Tomašić  1,932 
15. N1-0098  Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity   2019 - 2022  PhD Lucija Peterlin Mašič  905 
16. J3-9256  Development of NOD2 agonists and dual NOD2/TLR7 agonistic conjugates as novel vaccine adjuvants   2018 - 2022  PhD Žiga Jakopin  2,849 
17. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   2018 - 2021  PhD Lucija Peterlin Mašič  2,242 
18. J1-8140  Endocrine disrupting and genotoxic potential of protein kinase inhibitors: relevance for environmental hazard in zdravje ljudi   2017 - 2020  PhD Metka Filipič  3,794 
ARIS research and infrastructure programmes Legend
source: ARIS
International projects
no. Code Title Period Head No. of publications
1. CELSA/23/031  Exploiting structural insights in IP3 receptor function to develop novel, allosteric inhibitors of IP3 receptor channels (SINFONIC)   10/1/2023 - 9/30/2025     
2. COST-CA15135  Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)   4/18/2016 - 4/17/2020     
3. COST-CM1307  Targeted chemotherapy towards diseases caused by endoparasites   3/12/2014 - 3/11/2018     
Views history
Favourite